The FDA granted accelerated approval to Lartruvo for STS (olaratumab). This infusion is produced by Eli Lilly and Company, to treat adults with certain types of soft tissue sarcoma (STS). It is approved for use with doxorubicin for the treatment of STS patients:
- Who cannot be cured with radiation or surgery.
- For which chemotherapy is an appropriate treatment are approved for treatment.
Lartruvo for STS received orphan drug designation. It is a platelet-derived growth factor receptor-alpha blocking antibody. When stimulated, PDGF receptors cause tumor growth. Lartruvo blocks these receptors, helping to slow or stop tumor growth.
Lartruvo has serious risks including:
- Infusion-related reactions and embryo-fetal harm.
- Infusion-related reactions include low blood pressure, fever, chills and rash.
- The most common side effects of treatment with Lartruvo are nausea, fatigue, neutropenia, musculoskeletal pain, mucositis, alopecia, vomiting, diarrhea, decreased appetite, abdominal pain, neuropathy and headache.
ABOUT LATRUVO FOR STS: FROM THE LARTRUVO WEBSITE
WHAT IS STS?
Soft tissue sarcoma, or STS, is a cancer that begins in the soft tissues of the body. This can include the muscles, tendons, fat, blood vessels, or other supporting tissue.
SOFT TISSUE SARCOMA
There are many different kinds of STS, which are often referred to as subtypes. Some common subtypes are leiomyosarcoma (LMS)and liposarcoma, though there are many other types that appear and behave differently.
HOW COMMON IS STS?
Approximately 12,000 people in the U.S. will be diagnosed with STS in 2017. STS is considered a rare cancer.